These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6766971)

  • 1. The ninth component of human complement: purification and physicochemical characterization.
    Biesecker G; Müller-Eberhard HJ
    J Immunol; 1980 Mar; 124(3):1291-6. PubMed ID: 6766971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification and characterization of the eighth and ninth components of carp complement.
    Uemura T; Yano T; Shiraishi H; Nakao M
    Mol Immunol; 1996 Aug; 33(11-12):925-32. PubMed ID: 8960116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of late complement components by affinity chromatography: I. Purification of the human complement component C9 and production of a C9-defective human serum.
    Rauterberg EW; Schieck C; Hänsch G
    Z Immunitatsforsch Immunobiol; 1979 Jun; 155(5):365-77. PubMed ID: 112795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of the ninth component of the bovine complement cascade.
    Eisenschenk FC; Houle JJ; Hoffmann EM
    Am J Vet Res; 1992 Apr; 53(4):435-9. PubMed ID: 1586009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Purification of the ninth component of human complement (C9)].
    Zhou F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Oct; 14(5):389-93. PubMed ID: 1299546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of the ninth component of rabbit complement.
    Hänsch GM; Rummel G; Gänzler F
    Complement; 1984; 1(2):116-22. PubMed ID: 6544183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of the ninth component of complement in man.
    Inai S; Kitamura H; Hiramatsu S; Nagaki K
    J Clin Lab Immunol; 1979 Apr; 2(1):85-7. PubMed ID: 95812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of C9 in complement-mediated killing of Neisseria.
    Harriman GR; Esser AF; Podack ER; Wunderlich AC; Braude AI; Lint TF; Curd JG
    J Immunol; 1981 Dec; 127(6):2386-90. PubMed ID: 6795273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of C8 and C9 from rat serum.
    Jones J; Laffafian I; Morgan BP
    Complement Inflamm; 1990; 7(1):42-51. PubMed ID: 2323185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization.
    Tschopp J; Podack ER; Müller-Eberhard HJ
    J Immunol; 1985 Jan; 134(1):495-9. PubMed ID: 3964819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-deglycosylation of human complement component C9 reduces its hemolytic activity.
    Kontermann R; Rauterberg EW
    Mol Immunol; 1989 Dec; 26(12):1125-32. PubMed ID: 2633047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5b-9 complex of human complement.
    Bhakdi S; Bjerrum OJ; Bhakdi-Lehnen B; Tranum-Jensen J
    J Immunol; 1978 Dec; 121(6):2526-32. PubMed ID: 569173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH; Shin ML; Abramovitz AS; Mayer MM
    J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
    Morgan BP; Daw RA; Siddle K; Luzio JP; Campbell AK
    J Immunol Methods; 1983 Nov; 64(3):269-81. PubMed ID: 6199425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis of the monomeric and dimeric C5b-9 complexes of complement: alteration in the susceptibility to proteases of the C9 subunits associated with C5b-9 dimerization.
    Yamamoto K; Migita S
    J Immunol; 1981 Aug; 127(2):423-6. PubMed ID: 7019323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolytic modification of human complement protein C9: loss of poly(C9) and circular lesion formation without impairment of function.
    Dankert JR; Esser AF
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2128-32. PubMed ID: 3885222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased hemolytic activity of the trypsin-cleaved ninth component of complement.
    Tschopp J; Amiguet P; Schäfer S
    Mol Immunol; 1986 Jan; 23(1):57-62. PubMed ID: 3960033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid isolation of human complement component C9 to verify the specificity of a haemolytic C9 microassay.
    Bootsma HJ; van den Berg CW; van Dijk H
    J Chromatogr; 1992 Feb; 591(1-2):187-93. PubMed ID: 1613052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.